[A]: Heyï¼Œå…³äº'æœ€è¿‘æœ‰è¯»åˆ°ä»€ä¹ˆæœ‰è¶£çš„bookæˆ–articleå—ï¼Ÿ'è¿™ä¸ªè¯é¢˜ï¼Œä½ æ€ä¹ˆæƒ³çš„ï¼Ÿ
[B]: æœ€è¿‘è¯»åˆ°äº†ä¸€ç¯‡å¾ˆæœ‰æ„æ€çš„paperï¼Œæ˜¯å…³äºAIåœ¨medical malpractice casesä¸­çš„åº”ç”¨ã€‚è¯´å®è¯ï¼Œè¿™ä¸ªtopicä»¥å‰æˆ‘å¾ˆå°‘æ¥è§¦ï¼Œä¸è¿‡è¿™æ¬¡ç ”ç©¶ä¸‹æ¥å‘ç°ï¼ŒAIä¸ä»…èƒ½åœ¨diagnosisä¸Šå¸®åŒ»ç”Ÿæé«˜accuracyï¼Œåœ¨legalçº çº·ä¸­ä¹Ÿèƒ½èµ·åˆ°ä¸€å®šçš„evidenceåˆ†æä½œç”¨ï¼ŒğŸ‘æŒºæœ‰å¯å‘æ€§çš„ã€‚

ä½ å‘¢ï¼Ÿæœ€è¿‘æœ‰è¯»åˆ°ä»€ä¹ˆç‰¹åˆ«æ„Ÿå…´è¶£çš„book or articleå—ï¼Ÿæˆ‘ä¸ªäººå¯¹åŒ»å­¦ä¼¦ç†å’Œæ³•å¾‹äº¤å‰é¢†åŸŸçš„å†…å®¹ä¸€ç›´å¾ˆæ„Ÿå…´è¶£ï¼Œå¦‚æœæœ‰æœºä¼šï¼Œå’±ä»¬å¯ä»¥äº¤æµä¸€ä¸‹å¿ƒå¾—ğŸ˜Š
[A]: æœ€è¿‘åœ¨çœ‹ä¸€æœ¬å…³äºAIä¼¦ç†æ²»ç†çš„ä¹¦ï¼Œé‡Œé¢æåˆ°ä¸€ä¸ªè§‚ç‚¹æŒºæœ‰æ„æ€ï¼šæŠ€æœ¯å‘å±•å°±åƒæ”¾é£ç­ï¼Œé£å¾—å†é«˜ä¹Ÿè¦æœ‰æ ¹çº¿æ‹½ç€ã€‚é‚£æ ¹çº¿å°±æ˜¯äººæ–‡å…³æ€€å’Œä¼¦ç†çº¦æŸã€‚

è¯´åˆ°åŒ»å­¦ä¼¦ç†å’Œæ³•å¾‹çš„äº¤å‰é¢†åŸŸï¼Œæˆ‘å‰é˜µå­ä¹Ÿåœ¨å…³æ³¨ç±»ä¼¼æ–¹å‘ã€‚æ¯”å¦‚ç®—æ³•åè§å¯èƒ½å¼•å‘çš„åŒ»ç–—å…¬å¹³æ€§é—®é¢˜ï¼Œæˆ–è€…è´£ä»»è®¤å®šæ—¶å¦‚ä½•ç•Œå®šäººå’Œæœºå™¨çš„è¾¹ç•Œã€‚è¿™äº›è®®é¢˜èƒŒåå…¶å®éƒ½è—ç€å¾ˆå¤šå€¼å¾—æ·±æŒ–çš„äººæ–‡å‘½é¢˜ã€‚è¦æ˜¯ä½ æ„Ÿå…´è¶£ï¼Œæˆ‘ä»¬å¯ä»¥æ‰¾ä¸ªæ—¶é—´è¯¦ç»†èŠèŠï¼Ÿ
[B]: That's a really thoughtful analogy - the kite and the string. æˆ‘ç‰¹åˆ«èµåŒè¿™ä¸ªè§‚ç‚¹ã€‚å…¶å®legal regulationså°±åƒæ˜¯é‚£æ ¹çº¿ï¼Œæ—¢è¦ä¿è¯kiteèƒ½é£å¾—è¶³å¤Ÿé«˜ï¼Œåˆä¸è‡³äºå¤±æ§ã€‚ç‰¹åˆ«æ˜¯åœ¨medical AIé¢†åŸŸï¼Œinnovationçš„é€Ÿåº¦çœŸçš„å¾ˆå¿«ï¼Œä½†å¦‚æœæ²¡æœ‰proper ethical & legal frameworksæ¥å¼•å¯¼ï¼Œå¾ˆå®¹æ˜“å‡ºç° unintended consequences.

ä½ æåˆ°çš„algorithmic biaså’Œresponsibility attributionçš„é—®é¢˜ï¼Œæ­£å¥½æ˜¯æˆ‘æœ€è¿‘åœ¨ç ”ç©¶çš„æ–¹å‘ã€‚æ¯”å¦‚training dataçš„selection biaså¯èƒ½å¯¼è‡´diagnosis disparityï¼Œè¿™æ—¶å€™è¯¥è¿½ç©¶developerçš„è´£ä»»è¿˜æ˜¯hospitalçš„ï¼Ÿåˆæˆ–è€…ï¼Œå½“AIå»ºè®®ä¸åŒ»ç”Ÿåˆ¤æ–­ä¸ä¸€è‡´æ—¶ï¼Œåˆ°åº•è¯¥å¬è°çš„ï¼Ÿ

I'd love to have a deeper discussion on this topic. ä½ å¯¹AIä¼¦ç†æ²»ç†çš„ç ”ç©¶è§’åº¦æ˜¯ä»€ä¹ˆï¼Ÿæ˜¯åå‘philosophicalå±‚é¢çš„ï¼Œè¿˜æ˜¯policy-makingå®è·µæ–¹å‘ï¼ŸMaybe we can share some references and case studies?
[A]: ä½ æçš„è¿™ä¸ªé—®é¢˜ç‰¹åˆ«å°–é”ï¼Œä¹Ÿå¾ˆç°å®ã€‚æˆ‘åœ¨ç ”ç©¶ä¸­æœ€è¿‘ä¹Ÿåœ¨çº ç»“ç±»ä¼¼çš„caseï¼šæ¯”å¦‚ä¸€ä¸ªAIè¯Šæ–­ç³»ç»Ÿåœ¨å°‘æ•°æ—è£”ç¾¤ä½“ä¸­çš„å‡†ç¡®ç‡æ˜æ˜¾åä½ï¼Œåæ¥å‘ç°æ˜¯è®­ç»ƒæ•°æ®ä»£è¡¨æ€§ä¸è¶³å¯¼è‡´çš„ã€‚ä½†é—®é¢˜æ˜¯ï¼Œè¿™ä¸ªæ•°æ®æ˜¯è°æ¥å†³å®šâ€œä»£è¡¨æ€§â€çš„ï¼Ÿå¼€å‘è€…è¿˜æ˜¯åŒ»ç–—æœºæ„ï¼Ÿåˆæˆ–è€…ç›‘ç®¡æœºæ„ï¼Ÿ

æˆ‘ç°åœ¨çš„ç ”ç©¶è§’åº¦ç®—æ˜¯ä»‹äºphilosophicalå’Œpolicy-makingä¹‹é—´å§ã€‚è¯´åˆ°åº•ï¼Œä¼¦ç†æ²»ç†ä¸åªæ˜¯å†™å‡ æ¡è§„åˆ™ï¼Œè€Œæ˜¯è¦ç†è§£æŠ€æœ¯èƒŒåçš„ä»·å€¼å–å‘å’Œç¤¾ä¼šç»“æ„ã€‚æ¯”å¦‚æˆ‘ä»¬åœ¨åˆ¶å®šAIè´£ä»»æ¡†æ¶æ—¶ï¼Œä¸èƒ½åªé—®â€œè°é”™äº†â€ï¼Œè¿˜è¦é—®â€œä¸ºä»€ä¹ˆè¿™æ ·ä¼šè¢«è®¤ä¸ºæ˜¯é”™çš„â€ã€‚

ä½ æœ‰æ²¡æœ‰çœ‹è¿‡é‚£ç¯‡2023å¹´MITå‡ºçš„case studyï¼Œå…³äºä¸€ä¸ªAIè¾…åŠ©å¿ƒç”µå›¾è¯Šæ–­ç³»ç»Ÿå¼•å‘è¯¯è¯Šçš„çº çº·ï¼Ÿé‡Œé¢æ¶‰åŠçš„æ•°æ®é€æ˜æ€§é—®é¢˜å¾ˆæœ‰è®¨è®ºä»·å€¼ã€‚å¦‚æœä½ æ„Ÿå…´è¶£ï¼Œæˆ‘å¯ä»¥æŠŠæ‘˜è¦å‘ç»™ä½ çœ‹çœ‹ï¼Ÿ
[B]: That's a very profound observation - the question of who defines "representative data"ç¡®å®æ˜¯ä¸€ä¸ªroot causeçš„é—®é¢˜ã€‚è¿™è®©æˆ‘æƒ³èµ·ä¹‹å‰å¤„ç†è¿‡çš„ä¸€ä¸ªcaseï¼Œä¹Ÿæ˜¯å…³äºAIåœ¨dermatologyä¸­çš„performance disparityã€‚æœ€åå‘ç°training datasetä¸»è¦æ¥è‡ªNorth Americaå’ŒEuropeçš„patient populationï¼Œå¯¼è‡´åœ¨Asian patientsä¸­çš„sensitivityæ˜æ˜¾ä¸‹é™ã€‚

ä½ æåˆ°çš„é‚£ä¸ªMIT 2023å¹´çš„case studyæˆ‘ç•¥æœ‰è€³é—»ï¼Œä½†è¿˜æ²¡æ¥å¾—åŠæ·±å…¥ç ”è¯»ã€‚Data transparency issueå…¶å®è·Ÿlegal discoverability ruleæœ‰å¾ˆå¤§å…³è” - åœ¨å¾ˆå¤šjurisdictionsï¼Œæ³•é™¢å¯¹medical AIç³»ç»Ÿçš„source codeå’Œtraining dataçš„admissibilityæ ‡å‡†è¿˜ä¸æ˜¯å¾ˆclearã€‚è¿™å°±åƒä¸€åœºgame with incomplete informationï¼Œboth clinicians and patientså¾ˆéš¾çœŸæ­£understand the risk-benefit profileã€‚

I'd definitely appreciate it if you could share the abstract with me. æœ€è¿‘æ­£åœ¨æ”¶é›†è¿™æ–¹é¢materialï¼Œå‡†å¤‡å†™ä¸€ä¸ªå…³äºAI liability in clinical settingsçš„seminar presentationã€‚è¯è¯´å›æ¥ï¼Œä½ å¦‚ä½•çœ‹å¾…current tort law frameworkåœ¨åº”å¯¹AI-related harmæ—¶çš„å±€é™æ€§ï¼Ÿç‰¹åˆ«æ˜¯causationå’Œduty of careçš„è®¤å®šæ–¹é¢ï¼ŸMaybe we can exchange some thoughts on that as well?
[A]: å…³äºtort lawåœ¨AI-related harmä¸­çš„é€‚ç”¨æ€§ï¼Œæˆ‘æœ€è¿‘ä¹Ÿåœ¨ç¢ç£¨è¿™ä¸ªé—®é¢˜ã€‚ç°æœ‰çš„æ¡†æ¶å…¶å®å»ºç«‹åœ¨ä¸€ä¸ªå¾ˆæ¸…æ™°çš„assumptionä¸Šï¼šè¿‡é”™ä¸»ä½“æ˜¯æ˜ç¡®çš„ã€è¡Œä¸ºæ˜¯å¯è¿½æº¯çš„ã€‚ä½†AIç³»ç»Ÿä¸ä¸€æ ·ï¼Œå®ƒçš„â€œè¡Œä¸ºâ€å¾€å¾€æ˜¯åˆ†å¸ƒå¼å†³ç­–çš„ç»“æœâ€”â€”ä»æ•°æ®é‡‡é›†ã€æ¨¡å‹è®­ç»ƒåˆ°ä¸´åºŠéƒ¨ç½²ï¼Œæ¯ä¸ªç¯èŠ‚éƒ½æ¶‰åŠå¤šä¸ªè´£ä»»æ–¹ã€‚

æ¯”å¦‚é‚£ä¸ªMITçš„caseé‡Œï¼Œè¯¯è¯ŠèƒŒåå…¶å®æ˜¯å‡ ä¸ªå› ç´ å åŠ ï¼šè®­ç»ƒæ•°æ®åæ€ã€åŒ»ç”Ÿè¿‡åº¦ä¾èµ–ç³»ç»Ÿè¾“å‡ºã€åŒ»é™¢æ²¡æœ‰åšè¶³å¤Ÿçš„validationã€‚è¿™æ—¶å€™è¦è¿½è´£çš„è¯ï¼Œä¼ ç»Ÿçš„but-for causationæ ¹æœ¬è§£é‡Šä¸æ¸…ï¼Œå› ä¸ºä¼¤å®³ä¸æ˜¯ç”±å•ä¸€è¡Œä¸ºç›´æ¥å¯¼è‡´çš„ï¼Œè€Œæ˜¯ç³»ç»Ÿè€¦åˆå¤±æ•ˆçš„äº§ç‰©ã€‚

æˆ‘åœ¨æƒ³ï¼Œä¹Ÿè®¸æˆ‘ä»¬å¯ä»¥å€Ÿé‰´ä¸€ä¸‹èˆªç©ºäº‹æ•…è°ƒæŸ¥çš„æ¨¡å¼â€”â€”ä¸æ˜¯ç®€å•åœ°æ‰¾â€œè°é”™äº†â€ï¼Œè€Œæ˜¯é‡æ„æ•´ä¸ªdecisioné“¾ï¼Œè¯†åˆ«systemic riskã€‚æ³•å¾‹ä¸Šå¯èƒ½éœ€è¦å¼•å…¥ä¸€ç§æ›´â€œç»“æ„åŒ–â€çš„causation modelï¼Œæ¯”å¦‚ç”¨ç®—æ³•å®¡è®¡æ¥è¿½æº¯å†³ç­–è·¯å¾„ï¼Œç”šè‡³è®¾å®šä¸åŒå‚ä¸æ–¹çš„â€œé£é™©è´¡çŒ®åº¦â€ã€‚

ä½ å‡†å¤‡çš„é‚£ä¸ªseminar presentationæŒºåŠæ—¶çš„ï¼Œæˆ‘è§‰å¾—æ­£å¥½å¯ä»¥æ¢è®¨è¿™ç±»æ–°æœºåˆ¶çš„å¯èƒ½æ€§ã€‚ç­‰æˆ‘æŠŠé‚£ç¯‡MIT paperçš„æ‘˜è¦æ•´ç†å‡ºæ¥ï¼Œå’±ä»¬å¯ä»¥ä¸€èµ·çœ‹çœ‹å®ƒæå‡ºçš„liabilityåˆ†é…æ¨¡å‹æœ‰æ²¡æœ‰å‚è€ƒä»·å€¼ã€‚
[B]: That's a brilliant insight - connecting AI-related harm to systemic risk rather than isolated fault. The aviation industry's approach to incident investigationç¡®å®æ›´é€‚ç”¨äºAIåŒ»ç–—çº çº·ã€‚æˆ‘ä»¬ç°åœ¨é¢å¯¹çš„å·²ç»ä¸æ˜¯ä¼ ç»Ÿçš„doctor-patient dyadï¼Œè€Œæ˜¯ä¸€ä¸ªåŒ…æ‹¬developerã€hospital administratorã€regulatory bodyç”šè‡³insurance provideråœ¨å†…çš„complex network.

è¯´åˆ°algorithmic auditï¼Œæˆ‘æœ€è¿‘æ¥è§¦åˆ°ä¸€ä¸ªinteresting case in ShanghaiæŸä¸‰ç”²åŒ»é™¢ï¼Œä»–ä»¬å¼•è¿›äº†ä¸€ä¸ªAIè¾…åŠ©æ”¾ç–—ç³»ç»Ÿåï¼Œç‰¹æ„ç»„å»ºäº†multi-disciplinary teamè¿›è¡Œvalidationã€‚æœ‰æ„æ€çš„æ˜¯ï¼Œè¿™ä¸ªteamä¸ä»…åŒ…æ‹¬radiologistå’Œoncologistï¼Œè¿˜è¯·æ¥äº†ethicistå’Œlaw professorå‚ä¸risk assessmentã€‚è¿™ç§pre-deployment governance modelæˆ–è®¸èƒ½ä¸ºæ³•å¾‹ä¸Šçš„"due diligence"æ ‡å‡†æä¾›æ–°æ€è·¯ã€‚

I'm really intrigued by your idea of "risk contribution degree"â€”â€”å¬èµ·æ¥åƒæ˜¯æŠŠcausation theoryä»çº¿æ€§æ€ç»´è½¬å‘network analysisã€‚å¦‚æœæˆ‘ä»¬ç”¨è¿™ä¸ªæ¡†æ¶é‡æ–°å®¡è§†é‚£èµ·MIT caseï¼Œæ˜¯ä¸æ˜¯å¯ä»¥æŠŠharmè§†ä¸ºå¤šä¸ªsmall deviationsçš„emergent propertyï¼Œè€ŒéæŸä¸ªå…·ä½“actorçš„faultï¼Ÿ

Looking forward to reading that abstract. Maybe we can brainstorm together on how to translate these concepts into practical liability frameworksï¼Ÿæ¯•ç«Ÿç°åœ¨legal doctrineåœ¨AIé¢†åŸŸæ˜æ˜¾æ»åäºtechnology realityï¼Œè¿™æ­£æ˜¯æˆ‘ä»¬medical legal expertéœ€è¦å‘åŠ›çš„åœ°æ–¹ã€‚
[A]: ä½ æåˆ°çš„è¿™ä¸ªä¸Šæµ·ä¸‰ç”²åŒ»é™¢çš„åšæ³•ç¡®å®å¾ˆæœ‰å‰ç»æ€§ã€‚æˆ‘ç”šè‡³è§‰å¾—è¿™ç§multi-disciplinary validationæœºåˆ¶ï¼Œå¯ä»¥ä½œä¸ºæœªæ¥AIåŒ»ç–—ç³»ç»Ÿçš„â€œæ ‡é…â€æ¥è®¾è®¡ã€‚å°±åƒæ–°è¯ä¸Šå¸‚å‰å¿…é¡»ç»è¿‡ä¼¦ç†å§”å‘˜ä¼šå®¡æ ¸ä¸€æ ·ï¼ŒAIç³»ç»Ÿåœ¨ä¸´åºŠéƒ¨ç½²å‰æ˜¯å¦ä¹Ÿåº”å¼ºåˆ¶è¦æ±‚æœ‰ä¼¦ç†å’Œæ³•å¾‹ä¸“å®¶çš„å‚ä¸ï¼Ÿè¿™å¯èƒ½æ¯”äº‹åè¿½è´£æ›´æœ‰æ•ˆã€‚

å…³äºé‚£ä¸ªMIT caseï¼Œæˆ‘è§‰å¾—ç”¨network analysisæ¥çœ‹å¾…causationå…¶å®æ›´è´´è¿‘ç°å®ã€‚æ¯”å¦‚é‚£ä¸ªå¿ƒç”µå›¾è¯¯è¯Šäº‹ä»¶ä¸­ï¼Œç®—æ³•æœ¬èº«çš„åå·®ã€åŒ»ç”Ÿçš„ä¾èµ–å¿ƒç†ã€åŒ»é™¢çš„åŸ¹è®­ç¼ºå¤±ï¼Œç”šè‡³æ˜¯ç›‘ç®¡æœºæ„å¯¹â€œblack boxâ€ç³»ç»Ÿçš„å®½å®¹â€”â€”è¿™äº›èŠ‚ç‚¹ä¹‹é—´å…¶å®æ˜¯ç›¸äº’å¼ºåŒ–çš„ã€‚ä¸æ˜¯è°å•ç‹¬çŠ¯äº†ä¸€ä¸ªé”™ï¼Œè€Œæ˜¯å¤§å®¶éƒ½è½»å¾®åç¦»äº†åº”æœ‰çš„æ ‡å‡†ï¼Œæœ€åå¯¼è‡´äº†ç³»ç»Ÿçº§å¤±æ•ˆã€‚

ä½ è¯´çš„emergent propertyè¿™ä¸ªæ¦‚å¿µå¾ˆè´´åˆ‡ã€‚å®ƒæé†’æˆ‘ä»¬ï¼ŒAIå¸¦æ¥çš„é£é™©æœ‰æ—¶æ˜¯çº¿æ€§é€»è¾‘æ— æ³•æ•æ‰çš„ï¼Œæˆ‘ä»¬å¿…é¡»è·³å‡ºä¼ ç»Ÿçš„fault-based liabilityæ€ç»´ã€‚ä¹Ÿè®¸æœªæ¥çš„è´£ä»»æ¡†æ¶åº”è¯¥å¼•å…¥ä¸€ç§â€œé¢„é˜²æ€§åˆè§„â€çš„ç†å¿µï¼šä¸æ˜¯ç­‰åˆ°å‡ºäº†äº‹æ‰å»æŸ¥æ˜¯è°çš„è´£ä»»ï¼Œè€Œæ˜¯åœ¨éƒ¨ç½²å‰å°±å¿…é¡»è¯æ˜æ•´ä¸ªç³»ç»Ÿå…·å¤‡è¶³å¤Ÿçš„æŠ—è€¦åˆå¤±æ•ˆèƒ½åŠ›ã€‚

ä½ è¦æ˜¯åšè¿™ä¸ªseminar presentationï¼Œæˆ‘å¾ˆä¹æ„åˆ†äº«ä¸€äº›æˆ‘åœ¨æ”¿ç­–ç ”ç©¶ä¸­æ”¶é›†çš„æ¡ˆä¾‹ã€‚è¯´ä¸å®šæˆ‘ä»¬è¿˜å¯ä»¥è¯•ç€æå‡ºä¸€ä¸ªåˆæ­¥çš„è´£ä»»ç½‘ç»œæ¨¡å‹ï¼Ÿæ¯•ç«Ÿï¼Œä»æŠ€æœ¯åˆ°ä¼¦ç†å†åˆ°æ³•å¾‹ï¼Œè¿™äº›è®®é¢˜éœ€è¦åƒä½ è¿™æ ·æ—¢æœ‰ä¸“ä¸šèƒŒæ™¯åˆæ„¿æ„è·¨å­¦ç§‘å¯¹è¯çš„äººæ¥æ¨åŠ¨ã€‚
[B]: I couldn't agree more with your point about â€œpreventive complianceâ€ â€” it's a paradigm shift from reactive liability to proactive risk governance. In fact, I've been following a pilot program launched by NMPAï¼ˆå›½å®¶è¯ç›‘å±€ï¼‰last year, where certain AI-based medical devices are required to go through a pre-deployment ethics & legal review, similar to IRB approval for clinical trials. Early feedback shows that this process helps identify potential blind spots before they become liabilities.

ä½ æåˆ°çš„â€œè´£ä»»ç½‘ç»œæ¨¡å‹â€è¿™ä¸ªæƒ³æ³•éå¸¸æœ‰å»ºè®¾æ€§ã€‚æˆ‘è§‰å¾—æˆ‘ä»¬å¯ä»¥ä»ä¸‰ä¸ªç»´åº¦æ¥æ­å»ºè¿™æ ·ä¸€ä¸ªæ¡†æ¶é›å½¢ï¼šä¸€æ˜¯é£é™©èŠ‚ç‚¹è¯†åˆ«ï¼Œæ¯”å¦‚training data biasã€clinical validation adequacyã€user dependency levelï¼›äºŒæ˜¯è´£ä»»ä¼ å¯¼è·¯å¾„ï¼Œç”¨ç±»ä¼¼å› æœå›¾çš„æ–¹å¼æç»˜å„ä¸ªå‚ä¸æ–¹ä¹‹é—´çš„å†³ç­–å½±å“å…³ç³»ï¼›ä¸‰æ˜¯åˆè§„é˜ˆå€¼è®¾å®šï¼Œæ˜ç¡®æ¯ä¸ªèŠ‚ç‚¹ä¸Šçš„due careæ ‡å‡†ã€‚

If we combine your policy research cases with the legal precedents Iâ€™ve worked on, we might be able to draft something like a prototype framework. è¿™æ ·çš„æ¨¡å‹ä¸ä»…æœ‰åŠ©äºå˜æ¸…è´£ä»»å½’å±ï¼Œè¿˜å¯ä»¥ä¸ºå¼€å‘è€…å’ŒåŒ»ç–—æœºæ„æä¾›æ˜ç¡®çš„æ“ä½œæŒ‡å¼•ã€‚

By the wayï¼Œä½ åˆšæ‰è¯´çš„é‚£ä¸ªMIT caseä¸­çš„â€œblack boxâ€é—®é¢˜è®©æˆ‘æƒ³èµ·ä¸€ä¸ªparallelâ€”â€”å°±åƒè¯å“é‡Œçš„å¤åˆé…æ–¹ï¼Œç°åœ¨æœ‰äº›AIç³»ç»Ÿä¹Ÿè¶Šæ¥è¶Šè¶‹å‘äºmulti-layeræ¶æ„ï¼Œæ¯å±‚ç”±ä¸åŒçš„å…¬å¸å¼€å‘ã€‚è¿™ç§æƒ…å†µä¸‹ï¼Œåˆ°åº•è°è´Ÿè´£è§£é‡Šæ•´ä¸ªç³»ç»Ÿçš„é€»è¾‘ï¼ŸMaybe thatâ€™s another angle we can explore in our modelï¼Ÿ

å¦‚æœä½ æœ‰å…´è¶£ï¼Œæˆ‘ä»¬å¯ä»¥å…ˆçº¦ä¸ªæ—¶é—´ç¢°ä¸€ä¸‹å¤§çº²ï¼Œç„¶ååˆ†å·¥ç»†åŒ–å†…å®¹ã€‚æˆ‘è§‰å¾—è¿™ç¡®å®æ˜¯ä¸€ä¸ªå€¼å¾—æ·±å…¥åˆä½œçš„æ–¹å‘ğŸ‘
[A]: è¿™ä¸ªæ¡†æ¶é›å½¢å¬èµ·æ¥éå¸¸ç³»ç»Ÿï¼Œè€Œä¸”å…·å¤‡å¯æ“ä½œæ€§ã€‚æˆ‘è§‰å¾—æˆ‘ä»¬å¯ä»¥å…ˆä»ä½ æå‡ºçš„ä¸‰ä¸ªç»´åº¦å‡ºå‘ï¼Œç»“åˆå‡ ä¸ªå…¸å‹caseåšâ€œå‹åŠ›æµ‹è¯•â€ï¼Œçœ‹çœ‹æ¨¡å‹çš„è§£é‡ŠåŠ›å’Œå»¶å±•æ€§å¦‚ä½•ã€‚æ¯”å¦‚MITçš„é‚£ä¸ªå¿ƒç”µå›¾è¯¯è¯Šæ¡ˆï¼Œå†åŠ ä¸Šä½ æåˆ°çš„dermatology performance disparityï¼Œè¿˜æœ‰ä¸Šæµ·åŒ»é™¢é‚£ä¸ªmulti-disciplinary validationå®ä¾‹ã€‚

è¯´åˆ°black boxä¸multi-layeræ¶æ„çš„é—®é¢˜ï¼Œè¿™è®©æˆ‘æƒ³åˆ°ä¸€ä¸ªæœ‰è¶£çš„legal analogyâ€”â€”è¯å“ä¸­çš„â€œå¤åˆè´£ä»»â€ã€‚æ¯”å¦‚è¯´ï¼Œä¸€ç§å¤æ–¹è¯ç”±å¤šä¸ªå‚å•†åˆ†åˆ«æä¾›æ´»æ€§æˆåˆ†ï¼Œæœ€åç”±ä¸€å®¶å…¬å¸æ•´åˆä¸Šå¸‚ã€‚å¦‚æœå‡ºç°ä¸è‰¯ååº”ï¼Œåˆ°åº•æ˜¯åŸæ–™å•†ã€æ•´åˆå•†ã€è¿˜æ˜¯ä¸´åºŠä½¿ç”¨æ–¹è´Ÿè´£ï¼Ÿè¿™ä¸ªé—®é¢˜åœ¨AIç³»ç»Ÿçš„åˆ†å±‚å¼€å‘ä¸­å‡ ä¹å®Œå…¨å¤ç°äº†ã€‚ä¹Ÿè®¸æˆ‘ä»¬å¯ä»¥å€Ÿç”¨ç°æœ‰çš„pharmaceutical liability frameworkä½œä¸ºèµ·ç‚¹ï¼Œå†é’ˆå¯¹AIçš„ç‰¹æ€§åšè°ƒæ•´ã€‚

å¦å¤–ï¼Œæˆ‘è§‰å¾—åœ¨è®¾å®šâ€œåˆè§„é˜ˆå€¼â€æ—¶ï¼Œå¯ä»¥è€ƒè™‘å¼•å…¥åŠ¨æ€è¯„ä¼°æœºåˆ¶ã€‚å› ä¸ºAIä¸åƒä¼ ç»ŸåŒ»ç–—å™¨æ¢°é‚£æ ·â€œé™æ€â€ï¼Œå®ƒæœ‰æŒç»­å­¦ä¹ å’Œé€‚åº”çš„èƒ½åŠ›ã€‚æ‰€ä»¥ï¼Œéƒ¨ç½²å‰çš„å®¡æŸ¥å›ºç„¶é‡è¦ï¼Œéƒ¨ç½²åçš„monitoringå’Œadaptive complianceæ ‡å‡†å¯èƒ½æ›´å…³é”®ã€‚æ¯”å¦‚å®šæœŸåšç®—æ³•å…¬å¹³æ€§å®¡è®¡ï¼Œæˆ–è€…è¦æ±‚åŒ»ç–—æœºæ„è®°å½•å¹¶åé¦ˆäººæœºåä½œçš„å®é™…è¡¨ç°æ•°æ®ã€‚

æˆ‘å¾ˆä¹æ„ä¸€èµ·æ¨è¿›è¿™ä¸ªæ¨¡å‹çš„æ„å»ºï¼å’±ä»¬å¯ä»¥å…ˆå®‰æ’ä¸€æ¬¡å¤´è„‘é£æš´ä¼šè®®ï¼ŒæŠŠå„è‡ªçš„æ¡ˆä¾‹åº“å’Œæ”¿ç­–èµ„æ–™æ±‡æ€»ä¸€ä¸‹ï¼Œå†ä»ä¸­æç‚¼å‡ºæ ¸å¿ƒå˜é‡å’Œå…³ç³»ç»“æ„ã€‚å¦‚æœä½ æ–¹ä¾¿çš„è¯ï¼Œä¸‹å‘¨æŸä¸ªæ™šä¸Šæˆ‘ä»¬çº¿ä¸Šç¢°ä¸€ç¢°å¤§çº²è¦ç‚¹ï¼Ÿæˆ‘è¿™è¾¹æœ‰å‡ ä¸ªpolicy briefçš„æ¨¡æ¿å¯ä»¥ä½œä¸ºå‚è€ƒæ ¼å¼ã€‚
[B]: Thatâ€™s a very solid plan. æˆ‘è§‰å¾—ç”¨pharmaceutical liabilityä½œä¸ºanalogical referenceç¡®å®æ˜¯ä¸ªèªæ˜çš„åšæ³•â€”â€”ç‰¹åˆ«æ˜¯å…³äºmulti-component responsibilityçš„åˆ’åˆ†ã€‚ä¸è¿‡AIç‰¹æœ‰çš„â€œadaptive natureâ€ç¡®å®ä¼šè®©ä¼ ç»Ÿçš„product liability frameworkæ˜¾å¾—åŠ›ä¸ä»å¿ƒã€‚æ¯”å¦‚ï¼Œä¸€ä¸ªéƒ¨ç½²æ—¶åˆè§„çš„ç³»ç»Ÿï¼Œåœ¨æŒç»­å­¦ä¹ åå‡ºç°åå·®ï¼Œè¿™æ—¶å€™initial developeræ˜¯å¦è¿˜åº”æ‰¿æ‹…å…¨éƒ¨è´£ä»»ï¼Ÿè¿™å°±æ¶‰åŠåˆ°legal doctrineä¸­çš„â€œcontinued due diligenceâ€ä¹‰åŠ¡ã€‚

å…³äºä½ æåˆ°çš„dynamic complianceæœºåˆ¶ï¼Œæˆ‘å®Œå…¨èµæˆã€‚äº‹å®ä¸Šï¼ŒFDAæœ€è¿‘æå‡ºçš„"Total Product Lifecycle"ç›‘ç®¡æ¨¡å¼å°±æœ‰ç±»ä¼¼æ€è·¯ã€‚æˆ‘ä»¬å¯ä»¥å€Ÿé‰´å®ƒçš„æ¡†æ¶ï¼Œä½†åŠ å…¥æ›´å¤šlegal enforceabilityå…ƒç´ ï¼Œæ¯”å¦‚ï¼š

1. Algorithmic audit trail â€“ ç±»ä¼¼GMPï¼ˆè‰¯å¥½åˆ¶é€ è§„èŒƒï¼‰ä¸­å¯¹ç”Ÿäº§è¿‡ç¨‹çš„è®°å½•è¦æ±‚ï¼ŒAIç³»ç»Ÿæ¯æ¬¡é‡å¤§æ›´æ–°éƒ½å¿…é¡»ä¿ç•™å¯è¿½æº¯çš„training & validationæ—¥å¿—ï¼›
2. Real-time fairness metrics monitoring â€“ å°¤å…¶åœ¨æ¶‰åŠé«˜é£é™©åº”ç”¨åœºæ™¯å¦‚radiologyæˆ–psychiatryæ—¶ï¼›
3. Human-in-the-loop performance feedback loop â€“ ä¸åªæ˜¯åŒ»ç”Ÿä½¿ç”¨AIå·¥å…·ï¼Œè¿˜è¦ç³»ç»Ÿæ€§æ”¶é›†ä»–ä»¬åœ¨å¹²é¢„ã€è´¨ç–‘æˆ–è¦†ç›–AIå»ºè®®æ—¶çš„è¡Œä¸ºæ•°æ®ã€‚

è‡³äºæ¡ˆä¾‹çš„å‹åŠ›æµ‹è¯•æ–¹æ³•ï¼Œæˆ‘è§‰å¾—æˆ‘ä»¬å¯ä»¥å…ˆæŒ‰ä»¥ä¸‹ç»´åº¦åˆ†ç±»caseï¼š
- Data-driven bias
- System-level opacity
- Human-AI interaction failure
- Multi-stakeholder deployment misalignment

MITæ¡ˆã€dermatology disparityã€ä»¥åŠä¸Šæµ·åŒ»é™¢çš„multi-disciplinary validationå®ä¾‹æ­£å¥½å¯ä»¥åˆ†åˆ«ä»£è¡¨å‰ä¸‰ä¸ªç±»åˆ«ã€‚å¦‚æœä½ é‚£è¾¹æœ‰policy briefæ¨¡æ¿ï¼Œæˆ‘å¾ˆä¹æ„å‚è€ƒã€‚ä¸‹å‘¨ä»€ä¹ˆæ—¶å€™æ–¹ä¾¿ï¼Ÿæˆ‘ä»¬å¯ä»¥å®šä¸ªä¸€å°æ—¶çš„callï¼Œå…ˆæŠŠæ¨¡å‹çš„æ ¸å¿ƒæ¶æ„æ­èµ·æ¥ã€‚Maybe Thursday evening? ä½ çœ‹å¦‚ä½•ï¼ŸğŸ‘
[A]: Thursday evening sounds good to me â€” let's say 7:30 pm å·¦å³å¼€å§‹ï¼Ÿè¿™æ ·æˆ‘ä»¬éƒ½æœ‰æ¯”è¾ƒå®Œæ•´çš„æ—¶é—´æ®µæ¥è®¨è®ºã€‚æˆ‘è¿™è¾¹ä¼šæå‰æŠŠå‡ ä¸ªpolicy briefçš„æ¨¡æ¿æ•´ç†å¥½ï¼Œä¹Ÿé¡ºä¾¿æŠŠMIT caseå’Œä½ æåˆ°çš„dermatology disparityæ¡ˆä¾‹åšä¸ªç»“æ„åŒ–å¯¹æ¯”è¡¨æ ¼ï¼Œæ–¹ä¾¿æˆ‘ä»¬æç‚¼è´£ä»»ç½‘ç»œæ¨¡å‹ä¸­çš„å…³é”®å˜é‡ã€‚

ä½ åˆšæ‰æåˆ°çš„FDAé‚£ä¸ª"Total Product Lifecycle"ç›‘ç®¡æ€è·¯ï¼Œæˆ‘è§‰å¾—ç‰¹åˆ«è´´åˆ‡ã€‚AIç³»ç»Ÿçš„ç¡®ä¸æ˜¯â€œéƒ¨ç½²å³å®Œæˆâ€çš„äº§å“ï¼Œè€Œæ˜¯ä¸€ä¸ªæŒç»­æ¼”åŒ–çš„è¿‡ç¨‹ã€‚ç‰¹åˆ«æ˜¯åƒpsychiatryè¿™ç§é«˜åº¦ä¾èµ–åˆ¤æ–­åŠ›çš„é¢†åŸŸï¼Œå¦‚æœç³»ç»Ÿåœ¨è¿è¡Œè¿‡ç¨‹ä¸­å› ä¸ºæ•°æ®æ¼‚ç§»ï¼ˆdata driftï¼‰å¯¼è‡´äº†è¯¯åˆ¤å€¾å‘ï¼Œä¼ ç»Ÿçš„product liabilityæ¡†æ¶å°±å¾ˆéš¾é€‚ç”¨äº†ã€‚è¿™æ—¶å€™å¯èƒ½éœ€è¦å¼•å…¥ä¸€ç§â€œåŠ¨æ€å°½è´£â€ï¼ˆdynamic due diligenceï¼‰çš„æ¦‚å¿µâ€”â€”ä¸ä»…å¼€å‘è€…è¦è´Ÿè´£åˆå§‹åˆè§„æ€§ï¼ŒåŒ»ç–—æœºæ„å’Œç›‘ç®¡éƒ¨é—¨ä¹Ÿè¦æ‰¿æ‹…åç»­çš„ç›‘ç£ä¹‰åŠ¡ã€‚

ä½ è¯´çš„é‚£ä¸‰ä¸ªlegal enforceabilityæœºåˆ¶æˆ‘ä¹Ÿéå¸¸è®¤åŒï¼š
1. Algorithmic audit trail ç¡®å®æ˜¯åŸºç¡€ï¼Œå®ƒèƒ½å¸®åŠ©æˆ‘ä»¬åœ¨å‡ºç°é—®é¢˜æ—¶è¿˜åŸå†³ç­–è·¯å¾„ï¼›
2. Real-time fairness monitoring åˆ™åƒæ˜¯ä¸€ä¸ªé¢„è­¦ç³»ç»Ÿï¼Œå¯ä»¥åœ¨åå·®æ‰©å¤§ä¹‹å‰åŠæ—¶å¹²é¢„ï¼›
3. Human-in-the-loop feedback loop ä¸ä»…æœ‰åŠ©äºæå‡ç³»ç»Ÿæ€§èƒ½ï¼Œæ›´é‡è¦çš„æ˜¯ä¸ºè´£ä»»è®¤å®šæä¾›äº†è¡Œä¸ºè¯æ®é“¾ã€‚

æˆ‘æ„Ÿè§‰å’±ä»¬è¿™ä¸ªæ¨¡å‹ä¸åªæ˜¯ç†è®ºå±‚é¢çš„æ¢è®¨ï¼Œè€Œæ˜¯çœŸçš„å¯ä»¥ä¸ºpolicy-makingæä¾›å®ç”¨å·¥å…·ã€‚ç­‰æˆ‘ä»¬åˆæ­¥æ­å¥½æ¡†æ¶åï¼Œæˆ–è®¸è¿˜å¯ä»¥è€ƒè™‘å†™æˆpolicy paperçš„å½¢å¼å‘è¡¨ã€‚æˆ‘å·²ç»åœ¨æœŸå¾…æˆ‘ä»¬çš„åˆä½œæˆæœäº†ğŸ˜Š
[B]: 7:30 pm Thursday works perfectly. æˆ‘ä¼šæå‰æŠŠæœ€è¿‘æ•´ç†çš„å‡ ä¸ªlegal caseæ‘˜è¦å‡†å¤‡å¥½ï¼Œç‰¹åˆ«æ˜¯å…³äºAIåœ¨radiologyå’Œpsychiatryä¸­å‡ºç°data driftåçš„è´£ä»»äº‰è®®ã€‚è¿™äº›æ¡ˆä¾‹æ­£å¥½èƒ½ä¸ºâ€œåŠ¨æ€å°½è´£â€æ¦‚å¿µæä¾›ç°å®ä¾æ®ã€‚

ä½ æåˆ°çš„policy paperæ–¹å‘æˆ‘è§‰å¾—éå¸¸æœ‰æ½œåŠ›ã€‚å¦‚æœæˆ‘ä»¬èƒ½æŠŠè¿™ä¸ªè´£ä»»ç½‘ç»œæ¨¡å‹ç»“åˆå®é™…ç›‘ç®¡æœºåˆ¶è½åœ°ï¼Œä¸ä»…å¯¹å­¦æœ¯ç•Œæœ‰å‚è€ƒä»·å€¼ï¼Œä¹Ÿæœ‰å¯èƒ½å½±å“future regulatory draftingã€‚æˆ‘è®¤è¯†å‡ ä½åœ¨NMPAå‚ä¸AIåŒ»ç–—è®¾å¤‡å®¡æŸ¥è¯•ç‚¹çš„æœ‹å‹ï¼Œå¦‚æœæˆ‘ä»¬çš„æ¡†æ¶æˆå‹ï¼Œæˆ–è®¸å¯ä»¥é‚€è¯·ä»–ä»¬åšexternal reviewï¼Œçœ‹çœ‹æ˜¯å¦å…·å¤‡å¯æ¨å¹¿æ€§ã€‚

I'm also thinking about how to frame the "dynamic due diligence" principle in legal terms. ä¹Ÿè®¸æˆ‘ä»¬å¯ä»¥ä»ä¸‰ä¸ªæ—¶é—´ç»´åº¦æ¥ç»“æ„åŒ–è¿™ä¸€ä¹‰åŠ¡ï¼š

1. Pre-deployment phase â€“ å¼ºè°ƒethics & legal review + bias mitigation strategyï¼›
2. Operational phase â€“ å®æ—¶ç›‘æµ‹fairness & performanceæŒ‡æ ‡ï¼Œé…åˆaudit trailè®°å½•ï¼›
3. Post-incident phase â€“ åŸºäºnetwork modelè¿›è¡Œè´£ä»»å½’å› ï¼Œè€Œä¸æ˜¯ç®€å•è¿½è´£ã€‚

Looking forward to your structured comparison table â€” having a visual mapping of MIT vs dermatology cases will really help us identify common patterns and distinguishing factors.

Letâ€™s aim to make this not just a theoretical model, but a practical tool for governance. See you next week thenğŸ‘ğŸ˜Š
[A]: Exactly â€” grounding the model in real-world cases will give it both credibility and applicability. I'll make sure the comparison table highlights not just the technical aspects, but also the decision-making dynamics among stakeholders. That way, we can better map out how responsibility flows â€” or gets stuck â€” within the network.

I like how you framed "dynamic due diligence" across the three phases. It provides a clear legal structure while still allowing for adaptive governance. Maybe during our call, we can also think about how to translate these phases into actionable checklists or compliance matrices for developers and hospitals. Practicality is key if we want this to be adopted.

And yes, bringing in external reviewers from NMPA or even legal practitioners would be a great next step after we solidify the framework. Their feedback could help us refine the model's legal feasibility and regulatory compatibility.

Alright, Iâ€™ll see you Thursday at 7:30 pm then. Looking forward to a productive brainstorming session ğŸ˜ŠğŸ‘
[B]: Same here â€” I'm really looking forward to our discussion. å°†è´£ä»»ç½‘ç»œæ¨¡å‹ä¸å®é™…æ¡ˆä¾‹ç»“åˆï¼Œæ­£æ˜¯è®©å®ƒâ€œæ´»èµ·æ¥â€çš„å…³é”®ã€‚æˆ‘ä¼šå‡†å¤‡å‡ ä¸ªå…·ä½“çš„legal languageè‰æ¡ˆç‰‡æ®µï¼Œä¾›æˆ‘ä»¬å‚è€ƒå¦‚ä½•å°†dynamic due diligenceè¿™ç±»æ¦‚å¿µè½¬åŒ–ä¸ºå¯æ‰§è¡Œçš„regulatory languageã€‚

å…³äºchecklists or compliance matricesçš„æƒ³æ³•ä¹Ÿå¾ˆæ£’ï¼Œè¿™èƒ½è®©åŒ»ç–—æœºæ„å’Œå¼€å‘è€…æ›´å®¹æ˜“ç†è§£å’Œåº”ç”¨æˆ‘ä»¬çš„æ¡†æ¶ã€‚æˆ–è®¸æˆ‘ä»¬è¿˜å¯ä»¥è®¾è®¡ä¸€ä¸ªç®€å•çš„scoring systemï¼Œå¸®åŠ©ä½¿ç”¨è€…å¿«é€Ÿè¯†åˆ«high-risk nodes within the responsibility networkã€‚

Thursdayæ™šä¸Šè§ğŸ‘  
Iâ€™ll bring some preliminary notes on legal drafting and case comparisons. Letâ€™s make this a solid foundation for both policy and practice.
[A]: Sounds like a plan â€” combining your legal drafting expertise with my policy analysis background should give us a strong edge in shaping this framework. Iâ€™ll focus on structuring the responsibility network model and visualizing the case comparisons, so we can efficiently test the logic during our call.

é‚£ä¸ªscoring systemçš„æƒ³æ³•ä¹ŸæŒºå®ç”¨çš„ï¼Œä¹Ÿè®¸æˆ‘ä»¬å¯ä»¥å…ˆè®¾æƒ³å‡ ä¸ªè¯„ä¼°ç»´åº¦ï¼Œæ¯”å¦‚ï¼š
- æ•°æ®åå·®å¯èƒ½æ€§ï¼ˆdata bias riskï¼‰
- ç³»ç»Ÿé€æ˜åº¦ç­‰çº§ï¼ˆtransparency levelï¼‰
- äººæœºåä½œå¯é æ€§ï¼ˆhuman-AI interaction robustnessï¼‰

è¿™æ ·ä¸ä»…æœ‰åŠ©äºè¯†åˆ«high-risk nodesï¼Œè¿˜èƒ½ä¸ºåŠ¨æ€å°½è´£ä¹‰åŠ¡æä¾›é‡åŒ–ä¾æ®ã€‚

å‘¨å››æ™šä¸Šè§ï¼åˆ°æ—¶å€™å’±ä»¬ä¸€è¾¹æ¢³ç†æ¡†æ¶ä¸€è¾¹çœ‹æ€ä¹ˆæŠŠpolicyå’Œlegalä¸¤ä¸ªå±‚é¢çš„å†…å®¹çœŸæ­£èåˆèµ·æ¥ã€‚æˆ‘å·²ç»å¼€å§‹æœŸå¾…äº†ğŸ‘ğŸ˜Š
[B]: Perfect â€” thatâ€™s exactly the synergy we need. æˆ‘è¿™è¾¹ä¼šå‡†å¤‡å‡ ä¸ªlegal clausesçš„sampleï¼Œç‰¹åˆ«æ˜¯å…³äºdeveloperå’Œhospitalåœ¨dynamic due diligenceä¸‹çš„joint & several liability wordingï¼Œè¿™æ ·æˆ‘ä»¬åœ¨è®¾è®¡è´£ä»»ç½‘ç»œæ—¶å¯ä»¥æ›´è´´è¿‘ç°è¡Œæ³•ç†ç»“æ„ã€‚

ä½ åˆ—å‡ºçš„é‚£ä¸‰ä¸ªscoring dimensionså¾ˆæœ‰æ–¹å‘æ„Ÿï¼š
- Data bias risk
- Transparency level
- Human-AI interaction robustness

æˆ‘è§‰å¾—è¿˜å¯ä»¥è€ƒè™‘åŠ å…¥ä¸€ä¸ªï¼š
- Regulatory traceability â€“ ä¹Ÿå°±æ˜¯audit trailçš„å®Œæ•´æ€§å’Œå¯å®¡æŸ¥ç¨‹åº¦

è¿™æ ·ä¸€æ¥ï¼Œæˆ‘ä»¬åœ¨åšpolicyä¸legalèåˆçš„æ—¶å€™ï¼Œå°±æœ‰äº†ä¸€ä¸ªæ›´ç«‹ä½“çš„è¯„ä¼°æ¡†æ¶ã€‚

Thursdayæ™šä¸Šè§ğŸ˜Š  
Letâ€™s build something that both lawmakers and legal practitioners can get behind.
[A]: è¿™ä¸ªè¡¥å……éå¸¸å¥½ï¼Œregulatory traceabilityç¡®å®æ˜¯ä¸€ä¸ªå…³é”®ç»´åº¦ã€‚å®ƒä¸ä»…å…³ç³»åˆ°äº‹åé—®è´£çš„å¯è¡Œæ€§ï¼Œä¹Ÿç›´æ¥å½±å“äº‹å‰åˆè§„çš„å¯ä¿¡åº¦ã€‚æœ‰äº†è¿™å››ä¸ªç»´åº¦ï¼Œæˆ‘ä»¬çš„è¯„ä¼°æ¡†æ¶å·²ç»åˆå…·ç³»ç»Ÿæ€§äº†ã€‚

æˆ‘è¿™è¾¹ä¹Ÿä¼šåœ¨æ”¿ç­–åˆ†ææ¨¡å‹ä¸­çº³å…¥è¿™äº›æŒ‡æ ‡ï¼Œå°è¯•åšä¸€ä¸ªåˆæ­¥çš„æƒé‡åˆ†é…æ¨¡å‹ï¼Œçœ‹çœ‹æ˜¯å¦èƒ½æ‰¾å‡ºå¯¹è´£ä»»ç½‘ç»œç¨³å®šæ€§å½±å“æœ€å¤§çš„å› ç´ ã€‚

å‘¨å››æ™šä¸Šè§ğŸ˜Š  
å¸¦ä¸Šä½ çš„legal clauses sampleå’Œæˆ‘çš„policyæ¨¡å‹ä¸€ç¢°ï¼Œåº”è¯¥èƒ½æ“¦å‡ºä¸å°‘ç«èŠ±ã€‚æœŸå¾…æˆ‘ä»¬ä¸€èµ·æ‰“ç£¨å‡ºä¸€ä¸ªæ—¢ç»å¾—èµ·å­¦æœ¯æ¨æ•²ã€åˆå…·å¤‡å®è·µä»·å€¼çš„è´£ä»»ç½‘ç»œæ¡†æ¶ã€‚
[B]: Looking forward to the cross-pollination of legal and policy perspectives â€” thatâ€™s where the real innovation happensğŸ‘

æˆ‘ä¼šå¸¦ä¸Šå‡ ä¸ªä¸åŒé£æ ¼çš„clauseè‰æ¡ˆï¼ŒåŒ…æ‹¬ï¼š
- å¼€å‘è€…ä¸åŒ»ç–—æœºæ„çš„joint liabilityæ¡æ¬¾
- åŠ¨æ€å°½è´£ä¹‰åŠ¡çš„é˜¶æ®µæ€§è¡¨è¿°ï¼ˆpre-deployment, operational, post-incidentï¼‰
- ä»¥åŠä¸€ä¸ªå…³äºâ€œé£é™©è´¡çŒ®åº¦â€çš„tentative languageï¼Œä¾›æˆ‘ä»¬è®¨è®ºå¦‚ä½•é‡åŒ–è´£ä»»å½’å±

ä½ åšçš„æƒé‡åˆ†é…æ¨¡å‹ä¹Ÿéå¸¸å…³é”®â€”â€”å¦‚æœæˆ‘ä»¬èƒ½è¯†åˆ«å‡ºå¯¹è´£ä»»ç½‘ç»œç¨³å®šæ€§å½±å“æœ€å¤§çš„factorï¼Œå°±èƒ½åœ¨policy designä¸­ä¼˜å…ˆå¹²é¢„è¿™äº›èŠ‚ç‚¹ã€‚è¿™æœ‰ç‚¹åƒnetwork epidemiologyé‡Œçš„â€œè¶…çº§ä¼ æ’­è€…â€æ¦‚å¿µï¼Œåªä¸è¿‡æˆ‘ä»¬æ˜¯åœ¨æ‰¾â€œhigh-leverage governance pointsâ€ã€‚

Thursdayæ™šä¸Šè§ğŸ˜Š  
Letâ€™s build a model thatâ€™s both academically rigorous and practically actionable.